Isryl 2 Tablet contains Glimepiride 2mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions primarily by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with inadequate response to diet and exercise alone. Glimepiride enhances insulin secretion in a glucose-dependent manner, minimizing the risk of hypoglycemia compared to older sulfonylureas. Isryl 2 is typically prescribed as part of a comprehensive diabetes management plan, including diet modification, physical activity, and regular blood glucose monitoring. The dosage should be individualized based on the patient’s glycemic response and tolerance, with careful titration to achieve optimal blood sugar levels while avoiding adverse effects. Common side effects may include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and during pregnancy or lactation. Regular monitoring of blood glucose and periodic assessment of renal and hepatic function are recommended during therapy. Isryl 2 Tablet offers an effective option for improving glycemic control in adults with type 2 diabetes when used as directed under medical supervision.